• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Research Brief on tert-Butyl 3-(1-Cyano-1-Methylethyl)azetidine-1-carboxylate (CAS: 1466514-81-7)

The compound tert-butyl 3-(1-cyano-1-methylethyl)azetidine-1-carboxylate (CAS: 1466514-81-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This azetidine derivative is a key intermediate in the synthesis of various biologically active molecules, particularly in the development of novel therapeutics targeting protein-protein interactions and enzyme inhibition. Its unique structural features, including the azetidine ring and the tert-butyl carbamate protecting group, make it a versatile building block for medicinal chemistry applications.

Recent studies have highlighted the role of this compound in the synthesis of small-molecule inhibitors for kinases and other enzymes involved in critical signaling pathways. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of selective inhibitors for the PI3K/AKT/mTOR pathway, which is implicated in cancer progression. The compound's ability to introduce steric hindrance and modulate electronic properties has been leveraged to enhance the binding affinity and selectivity of these inhibitors.

In addition to its applications in oncology, tert-butyl 3-(1-cyano-1-methylethyl)azetidine-1-carboxylate has been employed in the design of neuroprotective agents. A recent preprint on bioRxiv detailed its use in the synthesis of compounds targeting the N-methyl-D-aspartate (NMDA) receptor, which plays a crucial role in neurodegenerative diseases such as Alzheimer's and Parkinson's. The study reported improved pharmacokinetic properties and reduced toxicity profiles for derivatives incorporating this azetidine scaffold.

From a synthetic chemistry perspective, the compound has been the subject of methodological advancements. A 2024 publication in Organic Letters described a novel asymmetric synthesis route for tert-butyl 3-(1-cyano-1-methylethyl)azetidine-1-carboxylate, utilizing chiral auxiliaries to achieve high enantiomeric purity. This development is particularly significant for the production of stereospecific pharmaceuticals, where enantiopurity is often critical for biological activity and safety.

Ongoing research continues to explore the potential of this compound in drug discovery. Current investigations include its incorporation into proteolysis-targeting chimeras (PROTACs) and other targeted protein degradation platforms. Preliminary results suggest that the azetidine moiety can enhance the physicochemical properties of these complex molecules, potentially addressing challenges related to cell permeability and metabolic stability.

In conclusion, tert-butyl 3-(1-cyano-1-methylethyl)azetidine-1-carboxylate (CAS: 1466514-81-7) represents a valuable scaffold in modern medicinal chemistry, with demonstrated applications across multiple therapeutic areas. Its continued exploration underscores the importance of heterocyclic chemistry in addressing current challenges in drug development. Future research directions may focus on expanding its utility in emerging therapeutic modalities and further optimizing synthetic approaches for industrial-scale production.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)